Puma Biotechnology, Inc.

NASDAQ:PBYI

Biotechnology

Healthcare
$7.22 +2.21%

+$0.16 today

Market cap
$373.26M
Beta
1.21
P/E (TTM)
15.4
EPS (TTM)
$0.48
52W Low $3.03High $7.90

Volume 0.45M

Average 0.26M

PBYI Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Puma Biotechnology, Inc.NASDAQ: PBYI

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows in line with its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 50.85M shares rose 1.9% year over year, behind the +3.4% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it fell 1.3% from the prior quarter. Over 3 fiscal years it compounded at +4.1% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +1.9% toward the trailing-twelve-month pace of +3.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
50.85M-1.3% QoQ
Last fiscal yearDec 2025
50.65M+3.2% YoY
LTMMar 2026
50.86M+3.4% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.9%——
1 year+3.2%——
3-year CAGR+4.1%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
50.65M USD
Year-over-year change
+3.2%
4-year CAGR
+5.7%

Weighted Avg Shares (Diluted) vs competitors

How PBYI compares with its peers on the latest reported figures

  • PBYI's LTM Mar 2026 weighted avg shares (diluted) of 50.86M shares is the 10th highest of the 11 companies compared; the peer median is 77.3M shares.
  • Its year-over-year change of +3.4% is the 8th highest of 11, against a peer median of +23.4%.
  • Over three fiscal years its annual growth of +4.1% compares with a peer median of +15.8%.
PBYI Competitors Peer median
Weighted Avg Shares (Diluted) for PBYI and competitors
Company Period LTM YoY 3-year CAGR
NUVBNuvation Bio Inc.LTM Jun 2026353.26M +9.5%+16.4%
TNGXTango Therapeutics, Inc.LTM Sep 2026145.89M +32.5%+9.8%
ONCYOncolytics Biotech Inc.LTM Mar 2026100.12M +27.6%+18.2%
ORICORIC Pharmaceuticals, Inc.LTM Mar 202692.59M +31.1%+30.3%
VSTMVerastem, Inc.LTM Mar 202682.44M +107.0%+62.5%
NBPNovaBridge BiosciencesLTM Sep 202572.17M -11.6%-20.4%
CRDFCardiff Oncology, Inc.LTM Mar 202667.15M +43.6%+15.3%
MGNXMacroGenics, Inc.LTM Mar 202663.26M +0.8%+0.9%
BDTXBlack Diamond Therapeutics, Inc.LTM Mar 202657.01M +0.9%+16.7%
PBYIPuma Biotechnology, Inc.LTM Mar 202650.86M +3.4%+4.1%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 202640.11M +19.2%+4.7%
Peer median (excluding PBYI) 77.3M+23.4%+15.8%

Competitors are the stored peer set for PBYI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue253.16M228.03M235.64M230.47M228.37M
Cost of Revenue63.7M55.09M62.68M64.4M58.16M
Gross Profit189.45M172.94M172.96M166.06M170.21M
Gross Margin74.8%75.8%73.4%72.1%74.5%
Research & Development71.87M52.24M50.38M54.94M62.07M
Selling, General & Admin116.29M89.98M89.31M80.16M71.21M
Operating Expenses188.16M149.22M140.32M135.1M132.92M
Depreciation & Amortization11.31M9.84M11.52M11.52M10.94M
EBITDA(4.69M)21.89M47.52M48.08M53.34M
EBITDA Margin-1.9%9.6%20.2%20.9%23.4%
Operating Income1.29M23.72M32.64M30.97M37.3M
Operating Margin0.5%10.4%13.9%13.4%16.3%
Interest Income160K813K2.61M4.72M4.08M
Interest Expense12.81M11.59M13.33M12.45M6.62M
Other Income / Expenses(30.09M)(23.26M)(9.97M)(6.87M)(1.52M)
Income Before Tax(28.8M)457K22.67M24.1M35.78M
Pre-Tax Margin-11.4%0.2%9.6%10.5%15.7%
Income Tax Expense324K455K1.08M(6.18M)4.67M
Net Income(29.13M)2K21.59M30.28M31.11M
Net Margin-11.5%0.0%9.2%13.1%13.6%
EPS (Basic)(0.72)0.020.460.620.62
EPS (Diluted)(0.72)0.020.450.620.61
Weighted Avg Shares40.64M44.67M47.13M48.65M50.01M
Weighted Avg Shares (Diluted)40.64M44.93M47.55M49.1M50.65M

Puma Biotechnology, Inc.

NASDAQ:PBYI

Intrinsic Alpha fair value

Locked

Current Price

$7.22

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.